Riociguat Oral Tablet ( DrugBank: Riociguat )

3 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
86	Pulmonary arterial hypertension	1
88	Chronic thromboembolic pulmonary hypertension	1

51. Scleroderma

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05339087 (ClinicalTrials.gov)	October 24, 2022	14/4/2022	Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH	Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)	Pulmonary Vascular Disorder;Primary Pulmonary Hypertension;Systemic Sclerosis;Other Systemic Involvement of Connective Tissue	Drug: Riociguat Oral Tablet;Other: Placebo	Heidelberg University	Merck Sharp & Dohme LLC	Recruiting	18 Years	N/A	All	70	Phase 2	Germany

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05339087 (ClinicalTrials.gov)	October 24, 2022	14/4/2022	Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH	Efficacy and Safety of Riociguat (MK-4836) in Incipient Pulmonary Vascular Disease as an Indicator for Early Pulmonary Arterial Hypertension Double-blind, Randomized, Multicenter, Multinational, Placebo-controlled Phase IIa Study (ESRA)	Pulmonary Vascular Disorder;Primary Pulmonary Hypertension;Systemic Sclerosis;Other Systemic Involvement of Connective Tissue	Drug: Riociguat Oral Tablet;Other: Placebo	Heidelberg University	Merck Sharp & Dohme LLC	Recruiting	18 Years	N/A	All	70	Phase 2	Germany

Clinical trials : 157 / Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04600492 (ClinicalTrials.gov)	October 16, 2020	19/10/2020	THERAPY-HYBRID-BPA Trial	The Effect of Riociguat for Peak Cardiac Index on Cardiopulmonary Exercise Test in CTEPH Patients After Normalization of Pulmonary Artery Pressure by Combination Treatment of Riociguat and Balloon Pulmonary Angioplasty	Hypertension, Pulmonary	Drug: Riociguat Oral Tablet	National Hospital Organization Okayama Medical Center	Bayer Yakuhin, Ltd.	Recruiting	18 Years	85 Years	All	72	Phase 2	Japan